This whitepaper describes the development and use of a cost model encompassing capital, labor, materials, consumables, and other costs, which are five key parameters of manufacturing for a variety of vaccine modalities: vaccines which use inactivated and attenuated viruses, protein subunit vaccines, virus-like particles (VLP) vaccines, Viral vector vaccines, and mRNA vaccines.
Get a step-by-step overview of the plasmid DNA manufacturing process and the challenges in pDNA downstream purification, for mRNA, plasmid-based DNA Vaccines, and Viral Vector applications.
Are you curious about Process Analytical Technologies (PAT), Raman spectroscopy, chemometrics and Raman applications in bioprocessing? Watch this 4 part interview series: PAT and Raman Meet the Experts Interview Series.
There is consensus among the global health community that long-term collaboration in resilient biomanufacturing capacity and supply chains…
recently commissioned Economist Intelligence Clearstate, a division of The Economist, to conduct a study on the future of…
The biopharmaceutical industry trends towards new product classes and smaller batch sizes drives even a greater need for…
